STAT July 2, 2024
Elaine Chen, Matthew Herper

Eli Lilly’s early Alzheimer’s treatment was approved by the Food and Drug Administration on Tuesday, making it the second drug on the U.S. market aimed at slowing progression of the debilitating neurological disease.

The treatment, whose scientific name is donanemab and will be sold under the brand name Kisunla, will compete with Eisai and Biogen’s Leqembi, which got full approval last...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Dermatology in 2024: FDA First Half Recap, with James Del Rosso, DO
FDA Study Finds Infectious H5N1 Bird Flu Virus In 14% Of Raw Milk Samples
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
Supreme Court to weigh whether the FDA was heavy-handed with flavored e-cigarette products
STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes

Share This Article